Skip to content 
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York. more
| Time Frame | AVXL | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -0.76% | 1.51% | -1.5% |
| 1-Month Return | -21.87% | 1.46% | 0.6% |
| 3-Month Return | 9.78% | 3.94% | 2.43% |
| 6-Month Return | -59.02% | 16.03% | 6.01% |
| 1-Year Return | -54.83% | 9.1% | 11.48% |
| 3-Year Return | -62.85% | 19.46% | 67.52% |
| 5-Year Return | -69.13% | 35.29% | 73.75% |
| 10-Year Return | 3.15% | 137.42% | 254.46% |
| Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Cost of Revenue | - | - | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Gross Profit | - | - | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Gross Margin | - | - | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Operating Expenses | 41.95M | 50.99M | 55.76M | 52.88M | 51.41M | [{"date":"2021-09-30","value":75.23,"profit":true},{"date":"2022-09-30","value":91.44,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":94.84,"profit":true},{"date":"2025-09-30","value":92.2,"profit":true}] |
| Operating Income | (41.92M) | (50.99M) | (47.50M) | (52.88M) | (51.41M) | [{"date":"2021-09-30","value":-4192100000,"profit":false},{"date":"2022-09-30","value":-5098600000,"profit":false},{"date":"2023-09-30","value":-4749800000,"profit":false},{"date":"2024-09-30","value":-5287700000,"profit":false},{"date":"2025-09-30","value":-5140800000,"profit":false}] |
| Total Non-Operating Income/Expense | 4.31M | 4.31M | 8.23M | 17.20M | 9.71M | [{"date":"2021-09-30","value":25.05,"profit":true},{"date":"2022-09-30","value":25.08,"profit":true},{"date":"2023-09-30","value":47.88,"profit":true},{"date":"2024-09-30","value":100,"profit":true},{"date":"2025-09-30","value":56.46,"profit":true}] |
| Pre-Tax Income | (37.64M) | (47.62M) | (47.50M) | (43.00M) | (46.38M) | [{"date":"2021-09-30","value":-3764100000,"profit":false},{"date":"2022-09-30","value":-4762000000,"profit":false},{"date":"2023-09-30","value":-4749800000,"profit":false},{"date":"2024-09-30","value":-4300200000,"profit":false},{"date":"2025-09-30","value":-4637700000,"profit":false}] |
| Income Taxes | 267.56K | 358.49K | (7.00K) | (2.29M) | (648.00K) | [{"date":"2021-09-30","value":74.64,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":-1.95,"profit":false},{"date":"2024-09-30","value":-639.07,"profit":false},{"date":"2025-09-30","value":-180.76,"profit":false}] |
| Income After Taxes | (37.91M) | (47.98M) | (47.49M) | (40.71M) | (45.73M) | [{"date":"2021-09-30","value":-3790856500,"profit":false},{"date":"2022-09-30","value":-4797849200,"profit":false},{"date":"2023-09-30","value":-4749100000,"profit":false},{"date":"2024-09-30","value":-4071100000,"profit":false},{"date":"2025-09-30","value":-4572900000,"profit":false}] |
| Income From Continuous Operations | (37.91M) | (47.98M) | (47.51M) | (43.00M) | (46.38M) | [{"date":"2021-09-30","value":-3790863400,"profit":false},{"date":"2022-09-30","value":-4797791900,"profit":false},{"date":"2023-09-30","value":-4750500000,"profit":false},{"date":"2024-09-30","value":-4300200000,"profit":false},{"date":"2025-09-30","value":-4637700000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Net Income | (37.91M) | (47.98M) | (47.49M) | (43.00M) | (46.38M) | [{"date":"2021-09-30","value":-3790900000,"profit":false},{"date":"2022-09-30","value":-4797800000,"profit":false},{"date":"2023-09-30","value":-4749100000,"profit":false},{"date":"2024-09-30","value":-4300200000,"profit":false},{"date":"2025-09-30","value":-4637700000,"profit":false}] |
| EPS (Diluted) | (0.53) | (0.62) | (0.60) | (0.52) | (0.54) | [{"date":"2021-09-30","value":-53,"profit":false},{"date":"2022-09-30","value":-62,"profit":false},{"date":"2023-09-30","value":-60,"profit":false},{"date":"2024-09-30","value":-52,"profit":false},{"date":"2025-09-30","value":-54.16,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| AVXL | |
|---|---|
| Cash Ratio | 20.68 |
| Current Ratio | 20.87 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| AVXL | |
|---|---|
| ROA (LTM) | -21.56% |
| ROE (LTM) | -33.64% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| AVXL | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| AVXL | |
|---|---|
| Trailing PE | NM |
| Forward PE | 3.85 |
| P/S (TTM) | 0.00 |
| P/B | 2.88 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
| PEG | NM |
Anavex Life Sciences Corp (AVXL) share price today is $4.04
Yes, Indians can buy shares of Anavex Life Sciences Corp (AVXL) on Vested. To buy
Yes, you can purchase fractional shares of Anavex Life Sciences Corp (AVXL) via the Vested app. You can start investing in Anavex Life Sciences Corp (AVXL) with a minimum investment of $1.
You can invest in shares of Anavex Life Sciences Corp (AVXL) via Vested in three simple steps:
The 52-week high price of Anavex Life Sciences Corp (AVXL) is $13.99. The 52-week low price of Anavex Life Sciences Corp (AVXL) is $2.86.
The price-to-earnings (P/E) ratio of Anavex Life Sciences Corp (AVXL) is
The price-to-book (P/B) ratio of Anavex Life Sciences Corp (AVXL) is 2.88
The dividend yield of Anavex Life Sciences Corp (AVXL) is 0.00%
The market capitalization of Anavex Life Sciences Corp (AVXL) is $364.20M
The stock symbol (or ticker) of Anavex Life Sciences Corp is AVXL
Consider the share price of Anavex Life Sciences Corp as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Anavex Life Sciences Corp has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Anavex Life Sciences Corp shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Anavex Life Sciences Corp stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Anavex Life Sciences Corp and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Anavex Life Sciences Corp stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
